# A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age

> **NCT05330975** · PHASE3 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 3317 (actual)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** mRNA-1345
- **BIOLOGICAL:** Afluria® Quadrivalent
- **BIOLOGICAL:** mRNA-1273.214

## Key facts

- **NCT ID:** NCT05330975
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-01
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 3317 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330975, "A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05330975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*